|COVIVAC vaccine is developed by the Health Ministry’s Institute of Vaccines and Medical Biologicals (IVAC). —VNA/VNS Photo
HÀ NỘI — The Prime Minister has decided to use over VNĐ8.8 billion from the national COVID-19 vaccine fund to support the first and second phase of clinical trials of the COVIVAC vaccine, which has been developed by the Health Ministry’s Institute of Vaccines and Medical Biologicals (IVAC) since May 2020.
COVIVAC uses viral vector technology on primary chicken embryo cell culture - a technique IVAC used previously to successfully produce seasonal flu vaccines. It is preserved at temperatures from 2-8 degrees Celsius.
In the first phase, it was evaluated as safe, well-tolerant and immunogenic.
The second phase will be carried out in Vũ Thư District, northern Thái Bình Province, with 375 volunteers.
COVIVAC is the second “made-in-Việt Nam” vaccine to be approved for clinical trials by the Health Ministry, following Nanogen company’s Nano Covax. — VNS